Oligodeoxyribonucleotides
"Oligodeoxyribonucleotides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of deoxyribonucleotides (up to 12) in which the phosphate residues of each deoxyribonucleotide act as bridges in forming diester linkages between the deoxyribose moieties.
| Descriptor ID |
D009838
|
| MeSH Number(s) |
D13.695.578.424.450
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Oligodeoxyribonucleotides".
Below are MeSH descriptors whose meaning is more specific than "Oligodeoxyribonucleotides".
This graph shows the total number of publications written about "Oligodeoxyribonucleotides" by people in this website by year, and whether "Oligodeoxyribonucleotides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 28 | 28 |
| 1994 | 0 | 6 | 6 |
| 1995 | 0 | 5 | 5 |
| 1996 | 1 | 4 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oligodeoxyribonucleotides" by people in Profiles.
-
Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response. Sci Rep. 2021 03 18; 11(1):6267.
-
Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide. J Control Release. 2017 Nov 28; 266:248-255.
-
Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses. Vaccine. 2016 05 05; 34(21):2453-2459.
-
Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm. 2015 Nov 30; 495(2):972-80.
-
Nanoparticle conjugation enhances the immunomodulatory effects of intranasally delivered CpG in house dust mite-allergic mice. Sci Rep. 2015 Sep 21; 5:14274.
-
Tuning the pH Response of i-Motif DNA Oligonucleotides. Chembiochem. 2015 Jul 27; 16(11):1647-56.
-
Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res. 2014 May; 2(5):436-47.
-
Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013 Nov 22; 342(6161):967-70.
-
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013 Dec 03; 110(49):19902-7.
-
Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation. Chem Commun (Camb). 2013 Oct 25; 49(83):9618-20.